Perspectives of Subcutaneous Velcade at Home of Patients With Myeloma.
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Patients experience of self-administration of Velcade
研究概览
简要总结
In the present study, we have trained 10 patients in subcutaneous self-administration of Velcade. After their training, patients will alternately receive their treatment in the hospital and at home by self-administration. In keeping with common practice, a nurse contacts the patients by telephone before 9.00 am on the day of treatment to ensure that the patient is physically "fit" to receive the medication and to discuss any side effects. To highlight the advantages and disadvantages of the changed treatment practice from the perspectives of both patients and healthcare professionals, data is collected from two consecutive semi-structured interviews with n = 10 patients and n = 1 focus group interview of the healthcare professionals involved. Moreover, time registration of medication administration both at the hospital and in the patients' home is done. The qualitative data will be analyzed via the method of condensation and continual quantitative data will form the basis of a cost-benefit analysis.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Patients experience of self-administration of Velcade
时间窗: Through study completion, from 01. dec. 2019 until 01. jun. 2022
Qualitative interviews with all 10 included patients
次要结局
- Health care perspective(Through study completion, from 01. dec. 2019 until 01. jun. 2022)
- Financial perspective(Through study completion, from 01. dec. 2019 until 01. jun. 2022)
- Organizational perspective(Through study completion, from 01. dec. 2019 until 01. jun. 2022)
研究者
Karin B. Ø. Dieperink
Nurse, PhD, Associate Professor
Odense University Hospital
